Fatty Acid Synthase (FASN)
Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.
Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.
All Product Categories
-
Fatty Acid Synthase (FASN) Inhibitors
(96)
View all products
-
Fatty Acid Synthase (FASN) Activators
(3)
View all products
-
Fatty Acid Synthase (FASN) Modulators
(2)
View all products
-
Fatty Acid Synthase (FASN) Chemicals
(4)
View all products
-
Fatty Acid Synthase (FASN) Control
(1)
View all products
-
Fatty Acid Synthase (FASN) Ligand
(1)
View all products
-
Fatty Acid Synthase (FASN) Related Products (115)
Related Products (115)
-
Antibodies (9)
-
Fasn Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04754Fasn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Fasn Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04755Fasn Rat Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
FASN Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04753FASN Human Pre-designed siRNA Set A contains three designed siRNAs for FASN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Procyanidin C2
0 ImagesCat. No.: HY-N7521CAS No.: 37064-31-6Synonyms: Procyanidine C2Procyanidin C2 (Procyanidine C2) is a lipid metabolism regulator and antioxidant with free radical scavenging activity. Procyanidin C2 down-regulates ACC, SREBP-1c, FAS, SCD-1 and PPARγ. Procyanidin C2 increases the level of phosphorylated AMPKα and inhibits the level of phosphorylated mTOR. Procyanidin C2 reduces lipid accumulation, alleviates oxidative stress, enhances fatty acid oxidation and improves mitochondrial function. Procyanidin C2 can be used in the research of non-alcoholic fatty liver disease.
-
UCM05 (Standard)
0 ImagesCat. No.: HY-110354RCAS No.: 1094451-90-7Synonyms: G28UCM (Standard)UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections[1][2][3].
-
GW-300
0 ImagesCat. No.: HY-16244CAS No.: 646989-21-1GW-300 is a SREBP cleavage-activating protein (SCAP) ligand that can be used for the study of endocrinology and metabolic disease.
-
FASN-IN-7
0 ImagesCat. No.: HY-15957CAS No.: 1579514-16-1FASN-IN-7 is a potent and orally active inhibitor of human Fatty Acid Synthase (FASN). FASN-IN-7 shows enzyme inhibition on full length FASN and the FASN KR domain with IC50 values of 28 and 54 nM. FASN-IN-7 effectively inhibits proliferation of multiple cancer cell types. FASN-IN-7 increases malonyl-CoA levels and decreases palmitate levels in tumor tissues.
-
QNX-10
0 ImagesCat. No.: HY-175020QNX-10 is a fatty acid synthase (FASN) inhibitor (IC50 = 0.7 μM) with anticancer activity. QNX-10 exhibits potent FASN inhibition and cytotoxicity against colorectal and breast cancer cells. QNX-10 induces apoptosis and cell cycle arrest in S phase by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-xL. QNX-10 can be used to investigate anticancer therapies targeting FASN enzymes.
-
PFM046
0 ImagesCat. No.: HY-170570CAS No.: 3053859-57-4PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models.
-
Pseudoprotodioscin (Standard)
0 ImagesCat. No.: HY-N0686RCAS No.: 102115-79-7Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
-
(R,S,S,S)-Orlistat
0 ImagesCat. No.: HY-172298CAS No.: 104872-28-8Synonyms: (R,S,S,S)-Tetrahydrolipstatin; (R,S,S,S)-Ro-18-0647(R,S,S,S)-Orlistat is a stereogenic derivative of orlistat (tetrahydrolipstatin; THL) (HY-B0218). (R,S,S,S)-Orlistat inhibits three Mycobacterium tuberculosis lipid esterases, Ag85C (KI: 16.43 μM), Rv3802 (EC50: 16.2 nM), and Pks13-TE.
-
(Rac)-NPD6433
0 ImagesCat. No.: HY-167879CAS No.: 895908-81-3(Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis.
-
CTL-06
0 ImagesCat. No.: HY-149540CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research.
-
Betulin (Standard)
0 ImagesBetulin (Standard) is the analytical standard of Betulin. This product is intended for research and analytical applications. Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.
-
PPAR agonist 7
0 ImagesCat. No.: HY-178958CAS No.: 3122526-69-3PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes.
-
1,3-Palmitin-2-docosahexaenoin
0 ImagesCat. No.: HY-149545CAS No.: 214038-32-1Synonyms: 1,3-Dipalmitoyl-2-docosahexaenoyl glycerol1,3-Palmitin-2-docosahexaenoin (1,3-Dipalmitoyl-2-docosahexaenoyl glycerol) is the isomer of triacylglycerol (TAG), in which docosahexaenoic acid (DHA) is located at the β position (sn-2) of the glycerol backbone. 1,3-Palmitin-2-docosahexaenoin inhibits fatty acid synthase and cholesterol metabolism enzymes, activates carnitine palmitoyltransferase (CPT) in liver mitochondria and promotes β-oxidation of fatty acids. 1,3-Palmitin-2-docosahexaenoin exhibits lipid metabolism regulating activity.
-
FASN/SCD-IN-1
0 ImagesCat. No.: HY-176274CAS No.: 3063509-61-2FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
-
Floramanoside F
0 ImagesCat. No.: HY-N17737CAS No.: 1487423-58-4Floramanoside F is a type of flavonol glycoside compound. Floramanoside F has a moderate free radical scavenging effect, with a SC₅₀ value of 25.1 μM. Floramanoside F has a relatively weak inhibitory activity on aldose reductase, with a IC₅₀ value greater than 100 μM. Floramanoside F has strong binding affinity with key target enzymes of type 1 diabetic nephropathy (T1DN) (Fasn, Cyp2e1, Cyp4a32), and can inhibit lipid accumulation and oxidative stress, thereby alleviating renal inflammation and fibrosis. Floramanoside F can be used to study type 1 diabetic nephropathy and diabetic complications.
-
W1307
0 ImagesCat. No.: HY-184891CAS No.: 3028770-95-5W1307 is a selective STAT3 inhibitor with a KD value of 1.74 μM. W1307 inhibits STAT3 Tyr705 phosphorylation, disrupts STAT3 dimerization, and suppresses STAT3 transcriptional activity. W1307 downregulates the expression of STAT3 downstream targets c-Myc, Mcl-1 and Bcl-2. W1307 transcriptionally inhibits SREBP1 and CPT2 expression to disrupt lipid homeostasis. W1307 shows potent anti-leukemic activity and synergizes with Cytarabine (Ara-C) (HY-13605) to overcome chemoresistance in acute myeloid leukemia (AML).
-
FASN-IN-6
0 ImagesCat. No.: HY-155282CAS No.: 3032387-88-2FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.
